GLP-2, or glucagon-like peptide-2, is a gut hormone whose primary job is maintaining and growing the lining of your intestine, not regulating body weight. Unlike its sibling hormone GLP-1, which has become famous through drugs like semaglutide, GLP-2 has no approved use for weight loss and is clinically used for the opposite problem: helping people with severely shortened intestines absorb enough nutrition to survive. Its relationship to body weight is genuinely paradoxical, though, because GLP-2 both suppresses appetite through brain circuits and ramps up how much fat your intestine pulls from food.
Where GLP-2 Comes From and How Quickly It Disappears
GLP-2 is cut from a larger precursor protein called proglucagon, the same molecule that gives rise to GLP-1 and glucagon. The difference comes down to which cells do the cutting. In the pancreas, processing enzymes carve out glucagon. In the L cells of the intestine, a different enzyme slices the other end of the molecule, producing both GLP-1 and GLP-2 at the same time.1Endocrinology. Proglucagon Processing Profile in Canine L Cells Expressing Endogenous Prohormone Convertase 1/3 and Prohormone Convertase 2 Every time you eat a meal and your L cells respond, they release GLP-1 and GLP-2 together. The two hormones are co-secreted, but they go on to do very different things.
GLP-2 does not last long in the bloodstream. In human studies, intravenously infused GLP-2 had a half-life of about seven minutes, meaning half of it was gone within that window.2The Journal of Clinical Endocrinology & Metabolism. In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in Humans The enzyme responsible for most of that breakdown is DPP-IV, the same enzyme that chews up GLP-1. DPP-IV clips two amino acids off the front of GLP-2, turning it into an inactive fragment called GLP-2(3-33). After a meal, roughly 57% of the GLP-2 circulating in human plasma was still intact, with the rest already degraded to that fragment.2The Journal of Clinical Endocrinology & Metabolism. In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in Humans Beyond DPP-IV, the kidneys, peripheral tissues, and the splanchnic bed (the blood vessels serving the gut) all clear intact GLP-2, though the liver does not.3PubMed. Metabolism of glucagon-like peptide-2 in pigs: role of dipeptidyl peptidase IV This rapid clearance is why therapeutic versions of GLP-2 had to be engineered to resist DPP-IV and last longer.
What GLP-2 Actually Does to Your Gut
The best-established action of GLP-2 is making the intestinal lining grow. In the landmark study that put GLP-2 on the map, administering it to mice stimulated crypt cell proliferation and produced visible increases in bowel weight and villus height in the jejunum and ileum within just four days.4PubMed. Induction of intestinal epithelial proliferation by glucagon-like peptide 2 The villi are the tiny finger-like projections that absorb nutrients; taller villi means more absorptive surface area. GLP-2 achieves this by activating growth factor pathways and triggering genes involved in cell division in the intestinal crypts, the stem-cell factories at the base of each villus.5PubMed Central. Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in mice
GLP-2 also strengthens the gut barrier. The intestinal lining relies on tight-junction proteins to seal the gaps between cells, preventing bacteria and their toxins from leaking into the bloodstream. GLP-2 boosts the production of key tight-junction proteins like occludin and ZO-1.6PubMed Central. The Effects of Glucagon-like Peptide-2 on the Tight Junction and Barrier Function in IPEC-J2 Cells through Phosphatidylinositol 3-kinase-Protein Kinase B-Mammalian Target of Rapamycin Signaling Pathway In obese mice, administering GLP-2 cut circulating levels of bacterial endotoxin by about 50%, a sign that the gut barrier was doing a better job keeping harmful molecules on the intestinal side where they belong.7Gut. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability That matters for metabolic health because endotoxin leaking through a compromised gut wall drives low-grade inflammation, which is linked to insulin resistance and other problems common in obesity.
On top of growing tissue and sealing it, GLP-2 increases blood flow to the gut. Human studies showed that a subcutaneous injection of GLP-2 increased blood flow through the superior mesenteric artery, the main vessel feeding the small intestine, by an amount comparable to eating a standard meal.8PubMed. Glucagon-like peptide-2 increases mesenteric blood flow in humans This response was dose-dependent and rapid, appearing within minutes of administration. Animal studies confirmed GLP-2 as a potent stimulator of mesenteric blood flow, and the effect appears to work independently of nitric oxide in the vasculature itself.9PubMed Central. GLP-2 and GIP acutely increase superior mesenteric artery blood flow in male rats, and the effect is independent of nitric oxide and vasoactive intestinal peptide More blood flow means more oxygen and nutrients for the rapidly dividing intestinal cells and more efficient pickup of absorbed food.
GLP-2 Increases Fat Absorption
Here is where the weight-loss question gets complicated. One of GLP-2’s established effects is boosting how much dietary fat your gut absorbs. In hamster studies, GLP-2 tripled the secretion of triglyceride-rich lipoproteins and cholesterol from the intestine after an olive-oil feeding, and this effect depended on the fat-transport protein CD36.10PubMed. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36 In other words, GLP-2 ramps up the intestinal machinery that packages dietary fat into particles called chylomicrons and ships them into the bloodstream.
A human study confirmed this directly. When researchers gave GLP-2 to people seven hours after a meal, when they had not eaten anything additional, it caused a robust spike in circulating triglycerides and chylomicron particles. Mathematical modeling suggested GLP-2 was releasing fat that had already been absorbed and was sitting in storage within the gut wall, waiting to be released.11PubMed Central. Glucagon-like peptide-2 regulates release of chylomicrons from the intestine The mechanism in animals involves a signaling cascade through nitric oxide synthase and protein kinase G in the gut, though human evidence suggests the systemic nitric oxide pathway is not required.12PubMed. GLP-2 Regulation of Dietary Fat Absorption and Intestinal Chylomicron Production via Neuronal Nitric Oxide Synthase (nNOS) Signaling13PubMed. Glucagon-like peptide-2 mobilizes lipids from the intestine by a systemic nitric oxide-independent mechanism
For someone interested in weight loss, this is the wrong direction. A hormone that makes your intestine grow bigger, increases its blood supply, and then helps it absorb more fat from meals is, at first glance, a hormone that should promote weight gain, not loss.
The Appetite-Suppression Side
Despite enhancing fat absorption, GLP-2 also acts on the brain to reduce food intake. Studies in mice showed that a DPP-IV-resistant form of GLP-2 dose-dependently reduced eating in both lean and diet-induced obese animals, with the appetite-suppressing effect kicking in within the first hour after injection.14Bioscientifica (Journal of Endocrinology). Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2 The effect lasted longer in lean mice (up to four hours) than in obese ones (about two hours), and overall, the appetite suppression was weaker in obese animals, hinting that obesity may blunt GLP-2’s brain signaling.
The brain mechanism involves a specific set of neurons in the hypothalamus called POMC neurons, the same hunger-regulation circuits targeted by GLP-1. Mice genetically engineered to lack GLP-2 receptors on POMC neurons became hyperphagic, meaning they overate, and also developed faster gastric emptying, glucose intolerance, and insulin resistance.15PubMed Central. The CNS glucagon-like peptide-2 receptor in the control of energy balance and glucose homeostasis When GLP-2 was delivered directly into the brain in those experiments, it improved glucose tolerance and suppressed liver glucose production through these same POMC-neuron pathways. In chick studies, injecting GLP-2 into the brain potently suppressed food intake, functioning as a strong appetite-reducing signal.16PubMed. Intracerebroventricular administration of chicken glucagon-like peptide-2 potently suppresses food intake in chicks
So GLP-2 can suppress appetite and improve glucose handling through the brain. But it simultaneously makes the gut better at extracting calories from whatever food you do eat. These opposing forces are why GLP-2 alone has never emerged as a viable weight-loss therapy.
How a High-Fat Diet Hijacks GLP-2
The paradox deepens when you look at what happens during chronic overeating. Mice fed a high-fat diet for 14 weeks showed significantly elevated GLP-2 blood levels and higher expression of GLP-2 receptors in the intestine. Their intestinal villi grew substantially: roughly 28-36% taller in the duodenum and jejunum, with a corresponding increase in cell proliferation.17PubMed. Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet When researchers blocked GLP-2 signaling with an antagonist, that intestinal overgrowth was reduced. This was the first experimental evidence that endogenous GLP-2 actively mediates the gut’s adaptation to a high-fat diet, essentially helping the intestine remodel itself to extract more calories from rich food.
This creates a feed-forward loop in obesity. Eating a high-fat diet raises GLP-2, which grows the intestinal lining, which increases fat absorption capacity, which may help sustain the obese state. An observational study in pregnant women found that maternal GLP-2 levels were significantly higher in women who gained excessive weight during pregnancy compared to those who gained the recommended amount.18PubMed Central. SERUM GLP-2 is Increased in Association with Excess Gestational Weight Gain While that does not prove GLP-2 caused the excess weight gain, it fits the pattern of GLP-2 being elevated in states of caloric surplus.
How GLP-2 Compares to GLP-1
Since GLP-1 and GLP-2 are co-released from the same cells at the same time, they are natural comparisons. GLP-1 has become the backbone of modern weight-loss pharmacology because it powerfully slows gastric emptying, suppresses appetite, and improves insulin signaling. GLP-2 shares some of these properties but is far less potent at the ones that matter most for weight.
A head-to-head human study measured how each hormone affects stomach emptying, a major contributor to feeling full. The highest dose of GLP-2 increased the time food stayed in the stomach by about 75%, while GLP-1 increased it by 192%.19PubMed. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1 GLP-2 does slow gastric emptying, but it takes a back seat to GLP-1 in that regard. And unlike GLP-1, GLP-2’s dominant peripheral actions (growing the gut, boosting fat absorption) push in the opposite direction from weight loss.
What GLP-2 Analogs Are Actually Used For
The only approved drug based on GLP-2 is teduglutide, a DPP-IV-resistant analog given by daily injection to patients with short bowel syndrome. These are people who have lost large portions of their intestine to surgery or disease and cannot absorb enough nutrition through eating alone, requiring intravenous feeding (parenteral nutrition) to survive. In a pivotal trial, 63% of patients on teduglutide reduced their need for intravenous nutrition compared with 30% on placebo. The average reduction was about 4.4 liters per week of parenteral support, and over half of teduglutide patients were able to skip at least one full day of intravenous feeding each week.20Gastroenterology. Teduglutide Reduces Parenteral Support Among Patients With Short Bowel Syndrome With Intestinal Failure In a mouse model of short bowel syndrome, teduglutide reduced body weight loss and decreased stool water and sodium losses, signs that the remaining intestine was working more efficiently.21PubMed Central. Teduglutide Promotes Epithelial Tight Junction Pore Function in Murine Short Bowel Syndrome to Alleviate Intestinal Insufficiency
Teduglutide is prescribed to help patients absorb more, not less. It is fundamentally a drug for people who need to gain nutritional ground, and it has never been studied or indicated for weight management in the general population.22PubMed. Use of teduglutide in adults with short bowel syndrome-associated intestinal failure
Dual GLP-1/GLP-2 Agonists and the Weight-Loss Question
The more interesting story for weight is whether combining GLP-1 and GLP-2 activity in one molecule offers something new. Two drugs in early development are testing exactly this idea.
Dapiglutide is a dual GLP-1/GLP-2 receptor agonist that was tested in a proof-of-concept trial for obesity. The results were underwhelming for weight loss: at the highest dose, participants lost an average of about 4.3% of their body weight over 12 weeks, but the placebo group lost 2.2%, making the difference between drug and placebo only about 2 percentage points and statistically nonsignificant. Where dapiglutide did show a clear benefit was in blood sugar control, with significant reductions in HbA1c compared to placebo.23The Lancet Diabetes & Endocrinology. Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial In a mouse model of short bowel syndrome, dapiglutide promoted body weight recovery and intestinal growth, which is consistent with the expected GLP-2 effect of improving nutritional absorption.24PubMed. Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel
A separate molecule called PG-102, designed as a bispecific GLP-1/GLP-2 fusion protein, is taking a different approach. In severely diabetic mice (db/db models) that were losing weight due to uncontrolled blood sugar, PG-102 achieved better and more sustained glucose control than semaglutide or tirzepatide while preserving body weight rather than causing further catabolic weight loss.25Nature Communications. Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial The mechanism appeared to involve preserving insulin-producing beta cells and enhancing glucose uptake through effects that required both receptors working together. The framing for PG-102 is not weight loss at all but rather uncoupling blood sugar control from the sometimes-unwanted muscle and weight wasting seen with pure GLP-1 drugs in advanced diabetes.
These early-stage drugs suggest the pharmaceutical interest in GLP-2 for metabolic disease is less about making people lose weight and more about adding gut-protective and glucose-lowering benefits to GLP-1’s established effects, or about preserving lean mass in patients who are already losing too much weight from aggressive GLP-1 therapy.
Safety Concerns Around Intestinal Growth
Any hormone that makes cells proliferate faster raises the question of cancer risk. The evidence on GLP-2 and intestinal tumors is a mix of concerning animal data and reassuring but limited human data.
In rodent models where cancer had already been initiated by a carcinogen, a long-acting GLP-2 analog increased the number of precancerous lesions in the colon by about 72%. In a longer study, rats treated with the GLP-2 analog developed colon cancer at a 22% rate compared to 0% in untreated rats.26PubMed. Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer Separately, rodent studies have shown that exogenously administered GLP-2 increases the growth and incidence of adenomas in the colon.27The Journal of Clinical Endocrinology & Metabolism. The Intestinotrophic Effects of Glucagon-Like Peptide-2 in Relation to Intestinal Neoplasia
A systematic review pooling human and animal data found that GLP-2 treatment for up to 30 months in humans without pre-existing cancer did not increase the risk of intestinal tumors. However, in animals with pre-induced cancers, GLP-2 appeared to promote the growth of existing tumors. The reviewers cautioned that too few human patients had been studied to draw final conclusions.28PubMed. Glucagon like peptide-2 and neoplasia; a systematic review This is one reason teduglutide comes with screening requirements: patients are monitored for polyps before and during treatment, and those with active gastrointestinal malignancy are excluded.
An Evolutionary Clue to GLP-2’s Role
One reason GLP-2 behaves so differently from GLP-1 despite being cut from the same precursor may lie in evolutionary history. Analysis of proglucagon sequences across vertebrates found that GLP-2 underwent rapid evolution specifically in the early mammalian lineage, suggesting it acquired a new biological function not present in fish, amphibians, or reptiles.29PubMed. Molecular evolution of proglucagon Among mammals, GLP-2 sequences show more variability than other proglucagon-derived peptides, and its receptor has the fastest protein-sequence evolution in the family, yet most of those changes are not predicted to alter function drastically.30PubMed Central. Variation in the Evolution and Sequences of Proglucagon and the Receptors for Proglucagon-Derived Peptides in Mammals
The implication is that GLP-2’s intestinal-growth role may have become important as mammals developed longer, more complex guts to handle varied diets. Its function evolved to maintain intestinal health and adapt absorptive capacity to changing nutritional demands, which is exactly what we see it doing today. That function is valuable for survival in environments where food is scarce and calorie extraction needs to be maximized. In modern food-abundant environments, where the problem is too many calories rather than too few, the same adaptation works against weight loss efforts. GLP-2 is, in a sense, a hormone shaped by famine, living in an age of feast.
Neonatal and Pediatric Research
An emerging area for GLP-2 research involves newborns with intestinal injury. Necrotizing enterocolitis is a devastating condition in premature infants where portions of the gut become inflamed and die. Researchers recently found that increasing GLP signaling (both GLP-1 and GLP-2) in human intestinal organoids, miniature lab-grown gut structures derived from neonatal tissue, enhanced the maturation of organoids from both injured and uninjured intestine.31PubMed. Glucagon-like peptides agonists promote maturation of intestinal organoids derived from neonates with necrotizing enterocolitis This is still far from a clinical treatment, but it reinforces GLP-2’s core identity as a gut-repair hormone and opens the possibility of therapeutic use in one of the most vulnerable patient populations. The weight-loss angle is irrelevant here; what matters is whether GLP-2 can help a damaged infant gut heal and grow enough to function.